BioLineRx Secures Patent for GLIX1, Enhancing Cancer Treatment Potential

BioLineRx Strengthens Intellectual Property for Cancer Treatment Candidate GLIX1

BioLineRx Ltd., a company dedicated to advancing oncology and rare disease therapies, announces a pivotal step in its clinical journey with the recent issuance of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO). This patent, which covers the application of GLIX1, a promising cancer treatment candidate, solidifies the company’s intellectual property position and extends protection until 2040, with a possibility of a five-year extension. Entitled 'Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies,' this patent is particularly significant as it encompasses over 90% of cancer types where cytidine deaminase (CDA) is not over-expressed, broadening the potential application of GLIX1 beyond its initial focus on glioblastoma.

The implications of this patent are profound for BioLineRx, as it not only enhances the commercial viability of GLIX1 but also empowers the company to pursue further research and development across a wider spectrum of cancer types. CEO Philip Serlin emphasizes that this patent reinforces BioLineRx's strategic direction, allowing for the exploration of GLIX1’s efficacy in treating various malignancies. The company is gearing up to initiate its first-in-human study for GLIX1 in glioblastoma in early 2026, while simultaneously advancing pre-clinical studies that target multiple cancer models. This dual approach of clinical and pre-clinical exploration positions BioLineRx to capitalize on GLIX1’s unique mechanism of action, which focuses on the DNA damage response in cancer cells, potentially leading to innovative treatment solutions for patients facing challenging cancer diagnoses.

In addition to the newly granted patent, GLIX1 is backed by a robust global portfolio of patents that protect its use as both a standalone treatment and in combination with existing anti-cancer therapies. This includes applications in central nervous system cancers and in conjunction with PARP inhibitors for homologous recombination-proficient tumors. The comprehensive patent strategy not only safeguards BioLineRx’s innovations but also underscores its commitment to advancing therapeutic options in oncology, paving the way for potentially groundbreaking advancements in cancer care.

As BioLineRx moves forward, the development and protection of GLIX1 illustrate the company’s dedication to addressing unmet medical needs within oncology. The upcoming clinical trials and expanded research could significantly enhance treatment paradigms for patients dealing with various forms of cancer, marking a crucial chapter in the ongoing battle against these diseases.